St. Jude Medical Inc. (NYSE:STJ)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $84.00 and last traded at $83.58, with a volume of 498,101 shares. The stock had previously closed at $83.90.

A number of equities analysts have issued reports on the company. JPMorgan Chase & Co. reiterated a “hold” rating on shares of St. Jude Medical in a report on Sunday, July 17th. Canaccord Genuity reiterated a “hold” rating on shares of St. Jude Medical in a report on Saturday, April 30th. Leerink Swann restated a “buy” rating on shares of St. Jude Medical in a report on Saturday, April 23rd. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective (up previously from $70.00) on shares of St. Jude Medical in a report on Wednesday, April 20th. Finally, Wells Fargo & Co. restated a “hold” rating on shares of St. Jude Medical in a report on Saturday, April 30th. Twenty-two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $75.93.

The stock’s 50-day moving average price is $80.59 and its 200 day moving average price is $67.35. The stock has a market cap of $23.85 billion and a price-to-earnings ratio of 36.40.

St. Jude Medical (NYSE:STJ) last released its earnings results on Wednesday, July 20th. The medical technology company reported $1.06 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.06. The company earned $1.56 billion during the quarter, compared to analysts’ expectations of $1.55 billion. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The firm’s revenue was up 10.8% compared to the same quarter last year. Equities analysts anticipate that St. Jude Medical Inc. will post $4.06 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 30th will be paid a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a yield of 1.48%. The ex-dividend date is Wednesday, September 28th.

Other hedge funds and institutional investors recently added to or reduced their stakes in the company. Marshall Wace LLP boosted its position in St. Jude Medical by 396.9% in the fourth quarter. Marshall Wace LLP now owns 286,788 shares of the medical technology company’s stock worth $17,715,000 after buying an additional 229,078 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in St. Jude Medical by 32.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 823,890 shares of the medical technology company’s stock worth $50,894,000 after buying an additional 199,858 shares during the last quarter. I.G. Investment Management LTD. boosted its position in St. Jude Medical by 29.7% in the fourth quarter. I.G. Investment Management LTD. now owns 228,600 shares of the medical technology company’s stock worth $14,121,000 after buying an additional 52,300 shares during the last quarter. Principal Financial Group Inc. boosted its position in St. Jude Medical by 4.3% in the fourth quarter. Principal Financial Group Inc. now owns 432,163 shares of the medical technology company’s stock worth $26,694,000 after buying an additional 17,640 shares during the last quarter. Finally, Suntrust Banks Inc. boosted its position in St. Jude Medical by 60.7% in the fourth quarter. Suntrust Banks Inc. now owns 41,483 shares of the medical technology company’s stock worth $2,561,000 after buying an additional 15,672 shares during the last quarter.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.